Lanreotide Acetate Injection
Product Images NDC 69097-870

Product Visual Gallery

This gallery contains 34 technical images submitted to the FDA as part of the official labeling for Lanreotide Acetate (NDC 69097-870). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig 1 (Fig 1)

An instructional diagram illustrating the components of a Lanreotide Acetate injection needle pack and syringe. The needle pack includes a green needle shield, green collar, needle inside, needle cap, and lid. The syringe consists of a barrel, cap, and plunger. The diagram labels each part clearly for assembly or use guidance.*

FDA Label Image

Fig 2 (Fig 2)

Illustration showing components and assembly of a lanreotide acetate injection needle pack. It depicts a clear needle cap, a needle with a green retractable shield where the needle is visible through a round window, and the combined needle pack with the needle enclosed inside.*

FDA Label Image

Fig 3 (Fig 3)

An instructional illustration showing a hand holding a syringe with a green needle shield. Text instructs not to touch the green needle shield, emphasizing it is not a cap, with a red X marking the area to avoid touching.*

FDA Label Image

Fig 4 (Fig 4)

An instructional illustration depicting the process of administering a subcutaneous injection using a syringe. The left side shows a hand pressing the plunger downward with a 20-second timer icon, while the right side shows the syringe barrel held in place, indicating proper injection technique.*

FDA Label Image

Fig 5 (Fig 5)

An instructional line drawing showing a single-use injection needle and its sterile packaging. A digital timer displays 30:00 minutes, indicating a wait or timing step related to the injection process for Lanreotide Acetate.*

FDA Label Image

Fig 6 (Fig 6)

An instructional illustration showing two depictions of a hand administering an injection into the buttock. The left side shows a correct injection technique with the hand making an 'OK' sign, while the right side shows an incorrect technique with a red X mark.*

FDA Label Image

Fig 7 (Fig 7)

An instructional diagram showing a 60 mg dose of Lanreotide Acetate injection in subcutaneous form. The image includes a labeled syringe or needle cap, a timer set to 30 minutes, and outlines possibly representing the injection site or steps for administration.*

FDA Label Image

Fig 8 (Fig 8)

An instructional illustration showing hands being washed under running water from a faucet, demonstrating proper hand hygiene technique.*

FDA Label Image

Fig 9 (Fig 9)

Packaging label for Lanreotide Acetate injection, showing the product name prominently. The label includes text details likely indicating strength and usage, with a design featuring a white background and a gray curved section. The labeler is Cipla USA Inc., though the exact strength visible in the image is not clear.*

FDA Label Image

Fig 10 (Fig 10)

An anatomical illustration showing the back view of a person standing. Two injection sites on the buttocks are marked with 'OK', indicating acceptable subcutaneous injection locations for the Lanreotide Acetate injection.*

FDA Label Image

Fig 11 (Fig 11)

An instructional illustration showing a person lying down on their stomach with potential injection sites marked as "OK" on the lower back area, demonstrating proper positioning for a subcutaneous injection.*

FDA Label Image

Fig 12 (Fig 12)

An illustration showing recommended subcutaneous injection sites on the upper buttocks. Two circular areas marked 'OK' indicate acceptable locations for administering the injection, positioned symmetrically below a dashed horizontal reference line.*

FDA Label Image

Fig 13 (Fig 13)

An instructional illustration showing a hand holding a cold pack against the upper buttock of a person. The image suggests applying cold therapy to this area, likely in relation to subcutaneous injection site care or preparation.*

FDA Label Image

Fig 14 (Fig 14)

An instructional line drawing showing hands opening a foil pouch containing a prefilled syringe or injection device labeled Lanreotide Acetate, demonstrating the preparation step for subcutaneous injection.*

FDA Label Image

Fig 15 (Fig 15)

An illustration showing hands holding a syringe with a green-labeled injection cartridge, demonstrating preparation or handling of a subcutaneous injection. The image is instructional, related to administering Lanreotide Acetate injection.*

FDA Label Image

Fig 16 (Fig 16)

An instructional diagram showing hands preparing a pre-filled injection syringe. The image focuses on holding the syringe barrel and plunger, illustrating the technique for handling or preparing a subcutaneous injection device, likely related to Lanreotide Acetate injection.*

FDA Label Image

Fig 17 (Fig 17)

An instructional illustration showing two hands holding a syringe-like device. The left hand holds the barrel, and the right hand grips the plunger, with an arrow indicating a twisting or turning action on the barrel, likely part of the preparation or administration process of the injection.*

FDA Label Image

Fig 18 (Fig 18)

An instructional illustration showing the removal of a cap from a syringe-like injection device for Lanreotide Acetate injection. The image depicts hands holding the device with an arrow indicating the direction to pull the plunger. It relates to the subcutaneous administration of the medication.*

FDA Label Image

Fig 19 (Fig 19)

An instructional diagram showing hands holding a syringe with a green needle shield. The text instructs not to touch the green needle shield, emphasizing that it is not a cap. A red cross mark highlights the area around the green needle shield.*

FDA Label Image

Fig 20 (Fig 20)

An instructional line drawing showing a hand giving an injection into the upper outer quadrant of a buttock. The illustration indicates the appropriate injection site for a subcutaneous injection.*

FDA Label Image

Fig 21 (Fig 21)

An instructional illustration showing a hand holding an injection device poised for subcutaneous injection into the upper arm, with a red X mark indicating that this site should not be used for the injection.*

FDA Label Image

Fig 22 (Fig 22)

An instructional diagram showing how to properly administer a subcutaneous injection with Lanreotide Acetate. It depicts a hand holding a syringe perpendicular at a 90-degree angle to the skin to ensure proper needle depth for a deep subcutaneous injection, with accompanying text emphasizing the importance of this angle.*

FDA Label Image

Fig 23 (Fig 23)

An instructional illustration showing a hand holding a syringe close to a user's skin, with a red X mark overlay indicating an incorrect injection technique or method to avoid.*

FDA Label Image

Fig 24 (Fig 24)

An instructional illustration demonstrating the proper removal of the green needle shield from a syringe. It emphasizes the full retraction of the green needle shield to ensure correct injection depth, showing hands holding the syringe with labeled parts including the plunger, green needle shield, and green collar.*

FDA Label Image

Fig 25 (Fig 25)

An instructional illustration showing how to use a prefilled syringe for injection. The diagram labels the plunger and syringe barrel, with an arrow indicating to hold the syringe for 20 seconds after injection to ensure proper administration.*

FDA Label Image

Fig 26 (Fig 26)

An instructional illustration showing a hand holding a syringe with a green needle shield. The syringe is positioned above the skin with an upward arrow indicating removal or detachment direction of the needle shield. This likely depicts a step in preparing the Lanreotide Acetate injection for subcutaneous administration.*

FDA Label Image

Fig 27 (Fig 27)

An instructional illustration showing a hand pressing a finger down on skin, with a downward arrow indicating the motion. This likely demonstrates a step in administering a subcutaneous injection of Lanreotide Acetate.*

FDA Label Image

Fig 28 (Fig 28)

An instructional illustration showing a hand holding a syringe with a green cap labeled "Check here." The image appears to guide users to check a specific part of the syringe, likely for proper preparation before subcutaneous injection.*

FDA Label Image

Fig 29 (Fig 29)

An instructional illustration showing a hand disposing of a medical needle into a sharps container labeled "SHARPS" with a biohazard symbol underneath. The image depicts safe disposal of injection needles.*

FDA Label Image

Chemical Structure (Str)

Chemical structure diagram showing the molecular formula of lanreotide acetate, with amino acid sequence notation and a variable group indicated as x(CH3COOH) where x ranges from 1.0 to 2.0.*

FDA Label Image

Figure 30.jpg (Figure 30)

A Kaplan-Meier survival curve showing progression-free survival probability over 24 months comparing Lanreotide Injection (n=101) and Placebo (n=103). The graph illustrates higher survival probabilities for Lanreotide across time, with a hazard ratio of 0.47 and P < 0.001. The number of subjects at risk decreases over time for both groups and is listed below the graph.*

FDA Label Image

60 mg/0.2 mL Carton Label (60mg Carton Label)

Lanreotide Injection 60 mg/0.2 mL subcutaneous injection carton label by Cipla USA Inc. The label states single-dose use with a pre-filled syringe and safety needle included. Storage instructions indicate refrigeration at 2°C to 8°C. The label features dosage strength clearly highlighted and manufacturer details, with a caution illustration on injection safety.*

FDA Label Image

90 mg/0.3 mL Carton Label (90mg Carton Label)

Lanreotide Injection 90 mg/0.3 mL subcutaneous injection carton labeled for deep subcutaneous use. The box indicates a single-dose, pre-filled syringe with one safety needle, manufactured by Cipla USA Inc. The packaging advises storage in refrigerated conditions and includes handling instructions and a caution against needle removal from the syringe. The NDC 69097-890-67 is shown on the front panel.*

FDA Label Image

120 mg/0.5 mL Carton Label (120mg Carton Label)

Lanreotide Injection 120 mg/0.5 mL subcutaneous injection carton label from Cipla USA Inc. The label states it contains one pre-filled syringe and one safety needle. It includes storage instructions to refrigerate and a warning about leaving the product at room temperature before administration. The label also features a syringe handling caution graphic and contact information for questions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.